Crossmark

Cost effectiveness of bevacizumab plus carboplatin paclitaxel versus carboplatin paclitaxel as front line for advanced ovarian cancer in Thailand

Published Online: 2025-03-22

Authors

Katanyoo, Kanyarat

Chaikledkaew, Usa

Chandeying, Nutthaporn
License Information

Text and Data Mining valid from 2025-03-22

Version of Record valid from 2025-03-22
More Information

Article History

Received: 19 October 2024

Accepted: 13 March 2025

First Online: 22 March 2025

Declarations

:

: The authors declare no competing interests.

Document is current